Zotepine – kdc

CLINICAL USE

Treatment of schizophrenia

DOSE IN NORMAL RENAL FUNCTION

25–100 mg 3 times a day

PHARMACOKINETICS

Molecular weight : 331.9

%Protein binding : 97

%Excreted unchanged in urine : <0.1 (40% as metabolites)

Volume of distribution (L/kg) : 50–168

half-life – normal/ESRD (hrs) : 14/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : 25 mg twice daily increasing to 75 mg twice daily

10 to 20 : 25 mg twice daily increasing to 75 mg twice daily

<10 : 25 mg twice daily increasing to 75 mg twice daily

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD : Unknown dialysability. Dose as GFR <10 mL/min

HD : Unknown dialysability. Dose as GFR <10 mL/min

HDF/high flux : Unknown dialysability. Dose as GFR <10 mL/min

CAV/VVHD : Unknown dialysability. Dose as GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Anaesthetics: enhanced hypotensive effect

Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids

Antidepressants: concentration increased by fluoxetine; concentration of tricyclics possibly increased

Anti-epileptics: antagonism, as convulsive threshold lowered

Antimalarials: avoid concomitant use with artemether/lumefantrine

Antivirals: concentration possibly increased by ritonavir Anxiolytics and hypnotics: enhanced sedative effects; concentration increased by diazepam

Sibutramine: increased risk of CNS toxicity – avoid concomitant use

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Do not use if there is a history of nephrolithiasis Occasionally can increase creatinine levels Undergoes extensive first pass metabolism .

Tags: post-by-auto-php